Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 M IN PLASTIC CONTAINER versus HEPATAMINE 8.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 M IN PLASTIC CONTAINER versus HEPATAMINE 8.
AMINOSYN 3.5% M IN PLASTIC CONTAINER vs HEPATAMINE 8%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% M is a mixture of essential and non-essential amino acids used for parenteral nutrition. It provides substrates for protein synthesis, thereby maintaining nitrogen balance and supporting tissue repair and growth.
HEPATAMINE 8% is a branched-chain amino acid (BCAA) solution that provides leucine, isoleucine, and valine to correct amino acid imbalances in hepatic encephalopathy. It reduces plasma aromatic amino acids (AAA) and increases BCAA, restoring the BCAA/AAA ratio, which decreases false neurotransmitter synthesis in the brain.
Intravenous infusion: 500 mL to 1 L of 3.5% amino acid solution per day for adults; rate not to exceed 0.1 g amino acids/kg/hr.
Intravenous infusion: 125 mL/hr initially, titrate to achieve positive nitrogen balance; typical adult dose: 125 mL/hr to 250 mL/hr via central line, not to exceed 2 g protein equivalent per kg per day.
None Documented
None Documented
Variable (minutes to hours) due to rapid metabolic utilization; terminal half-life in plasma is <10 minutes for most amino acids.
Variable; amino acids in HEPATAMINE 8% are cleared rapidly (t1/2 ~10-20 minutes for free amino acids) due to endogenous metabolism. In hepatic failure, half-life may be prolonged (patients with cirrhosis: up to 60 minutes for certain amino acids). Clinical context: supports continuous infusion for stable plasma levels.
Renal: >90% as amino acids and metabolites; negligible biliary/fecal elimination.
Renal: negligible as intact amino acids; nitrogen waste (urea) excreted renally (80-90% of infused nitrogen). Biliary/fecal: <5%.
Category C
Category C
Amino Acid Solution
Amino Acid Solution